Abstract

Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis.
Morie Gertz
American journal of hematology | VOL. 98
Morie GertzMorie Gertz
12 May 2023
Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis
Steven Burt ... Yubin Kang
Blood | VOL. 130
Steven Burt, et. al.Steven Burt ... Yubin Kang
25 Jun 2021
Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis
Richard Lafayette ... Michelle O'Shaughnessy
Blood | VOL. 132
Richard Lafayette, et. al.Richard Lafayette ... Michelle O'Shaughnessy
29 Nov 2018
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)
Palladini Giovanni ... Arnaud Jaccard
Blood | VOL. 124
Palladini Giovanni, et. al.Palladini Giovanni ... Arnaud Jaccard
06 Dec 2014
View more papers

More From: British journal of haematology

Paper Title
Journal
Date
Author
Recurrent ETV6::SYK rearrangement in myeloid malignancies confers partial susceptibility to MEK inhibition.
Karen Manuelyan ... Velizar Shivarov
British journal of haematology | VOL. -
Karen Manuelyan, et. al.Karen Manuelyan ... Velizar Shivarov
19 May 2024
Mixed histiocytic disorders: Nature versus nurture?
Kenneth Mcclain ... Peter Dimitrion
British journal of haematology | VOL. -
Kenneth Mcclain, et. al.Kenneth Mcclain ... Peter Dimitrion
19 May 2024
Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.
Paul J Bröckelmann
British journal of haematology | VOL. -
Paul J BröckelmannPaul J Bröckelmann
16 May 2024
A case of de novo -α3.7 thalassaemia and the utility of CATSA for detecting de novo mutations in thalassaemia.
Lei Zhang ... Weiqing Wu
British journal of haematology | VOL. -
Lei Zhang, et. al.Lei Zhang ... Weiqing Wu
16 May 2024
View more papers